elsevier – Retraction Watch

Judge tosses lawsuit over controversial Paxil ‘Study 329’

A judge has dismissed a legal challenge aimed at forcing Elsevier to retract a long-criticized study that concluded the antidepressant Paxil was safe and effective for teens.

The 2001 paper, published in the Journal of the American Academy of Child & Adolescent Psychiatry (JAACAP), has faced scrutiny for more than 20 years by critics who say the study has led to unwarranted and potentially harmful prescribing of the drug to youth. As we reported last October, the journal placed an expression of concern on the paper shortly after a lawsuit was filed by attorney George W. Murgatroyd III against the journal’s owner, the American Academy of Child and Adolescent Psychiatry (AACAP), and Elsevier, which publishes the title.

In his complaint, filed in the Superior Court of the District of Columbia, Murgatroyd claimed the journal is violating the D.C. Consumer Protection Procedures Act (CPPA) by continuing to “publish, distribute, and sell a fraudulent scientific article that contains material facts” that mislead the public and endanger adolescent mental health and safety. AACAP and Elsevier are profiting from the article by charging readers to buy access to the paper, according to the complaint.

Technology journal pulls papers for unauthorized author changes, fictitious emails

An Elsevier energy-technology journal has retracted six papers from 2022 whose authors changed without editorial approval during revision of the manuscripts.

The authors also provided fictitious email addresses during the submission process, but changed them after the papers were accepted, according to retraction notices in the February issue of Sustainable Energy Technologies and Assessments.

While the issues don’t necessarily indicate foul play, authorship changes and the use of non-institutional email addresses can be signs of paper-mill involvement. In 2021, we reported on a website in Iran that listed “articles ready for acceptance,” including one to appear in Sustainable Energy Technologies and Assessments. The year after our story, the journal pulled the paper, whose author list had also changed at the revision stage.

Chemist nears three dozen retractions for image duplication, self-citation and more

A screenshot of Louis’ LinkedIn profile before we reached out to him.

Racking up 35 retractions in just 24 months, chemist Hitler Louis has scored a place on our leaderboard.

The papers at issue, most of them published in Elsevier and Royal Society of Chemistry journals, exhibit a variety of problems, according to the retraction notices: identical plots supposedly representing different chemical systems, self-citations multiplying between manuscript submission and publication, compromised peer review and fundamental errors in chemical analyses.

Louis – who also goes by Louis Hitler Muzong – did not respond to Retraction Watch’s requests for comment. Until recently, his LinkedIn page named him as a Ph.D. student in computational chemistry at the University of Leeds in the United Kingdom, with an expected completion date of October 2027. But retraction notices for two papers say Louis requested his Leeds affiliation be removed. One states “the research described in the article is not associated with that institution,” and the other that the affiliation “was given incorrectly.” The University of Leeds did not respond to a request to verify whether he was a student there.

Mega-journal Heliyon retracts hundreds of papers after internal audit

Heliyon has published fewer papers and ramped up its retractions since a major indexing service put the journal on hold and the publisher launched an audit of all papers published in the journal since its launch in 2016.

Clarivate put Heliyon on hold in September 2024, citing concerns about the quality of the content. The “on-hold” status indicates a journal is being re-evaluated, and new content isn’t indexed, according to documentation on the Clarivate website. A spokesperson for Clarivate told us they couldn’t comment on specific journals, but said a journal must be both taken off hold and have its missing content backfilled by August 1 in order to receive an impact factor for that year. If a journal is still on hold and content hasn’t been backfilled, the journal will not receive an impact factor, the spokesperson said.

Heliyon published over 11,000 papers in 2023 and more than 17,000 in 2024, issuing around two dozen retractions in each year. Last year, the journal published 3,168 articles and retracted 392 others.

Finance professor in Ireland loses 12 papers in journals he edited

Elsevier has pulled a dozen papers by a finance professor in Ireland who oversaw the review of the articles and made “the final decision” to publish them in three journals he edited, according to the retraction notices.

The professor, Brian M. Lucey of Trinity College Dublin, and his coauthors disagreed with the retractions, which came a few days before Christmas.

“I’m not disputing the fact that I made the final decision” to publish the articles, some of which have garnered hundreds of citations, Lucey told us in an interview. ”What I’m disputing is that that is not prima facie grounds” for retracting them.

Journal removes funding statement from hormone therapy paper without issuing correction

A Cell Press journal quietly removed part of a funding statement from a paper related to gender-affirming hormone therapy that the authors say was included in error. Experts called the move “worrying.”

The authors of the paper, which appeared in Cell Reports on September 23, gave estrogen therapy to male monkeys to better understand how hormone therapies used in gender clinics might affect the immune system.

The research drew attention from several conservative news organizations, some of which called the project “disturbing” and alleged the work cost millions of dollars in National Institutes of Health funding.

Glyphosate safety article retracted eight years after Monsanto ghostwriting revealed in court

*Credit: Mike Mozart/Flickr (CC BY 2.0)*

A review article concluding the weed killer Roundup “does not pose a health risk to humans” has been retracted eight years after documents released in a court case revealed employees of Monsanto, the company that developed the herbicide, wrote the article but were not named as coauthors.

The safety of glyphosate, the active ingredient in Roundup, is hotly debated and currently under review at the U.S. Environmental Protection Agency. The International Agency for Research on Cancer, part of the World Health Organization, in 2015 declared glyphosate “possibly carcinogenic.”

The now-retracted article appeared in Regulatory Toxicology and Pharmacology, an Elsevier title, in 2000. Gary Williams, then a pathologist at New York Medical College in Valhalla, Robert Kroes, a toxicologist at the University of Utrecht in the Netherlands, and Ian C. Munro, a toxicologist at Cantox Health Sciences International in Ontario, Canada, were listed as the authors. The paper has been cited 614 times, according to Clarivate’s Web of Science.

Iraqi journal suspected of coercion, two others dropped from major citation databases

The influential citation database Scopus has delisted three journals from Iraq in a blow to recent government efforts to boost the standing of the country’s scholarly publications. One of the titles, which was included in Clarivate’s Web of Science, was dropped from that index as well.

Last month we reported on allegations that one of the delisted journals, the Medical Journal of Babylon, a publication of the University of Babylon in Hilla, was coercing authors to cite its articles. Citation manipulation is widespread in Iraq and elsewhere, but is considered a form of scientific misconduct.

“The Medical Journal of Babylon was flagged for re-evaluation at the end of September when we received concerns, and because we observed outlier publication performance,” said a spokesperson from Elsevier, which owns Scopus. The publisher marked the journal as delisted in its October update of indexed and delisted titles.

Botanists plant a stake in oral cancer research with case report, now under investigation

Elsevier is investigating a case report of a person with aggressive cancer, written by three plant researchers working far afield of their specialty.

The three authors of the study, published June 2024 in Oral Oncology Reports, purport to diagnose a 63-year-old man with a rare, aggressive form of oral cancer. The journal is a companion title to Elsevier’s Oral Oncology according to the homepage, but is not indexed in Clarivate’s Web of Science.

Corresponding author Velmani Sankaravel told Retraction Watch he and his colleagues found the case report from an “online open-access source” and then used it “to support our research on plant-based diagnostics for oral cancer.” However, the paper lists CT scans, biopsies, and other routine diagnostic tests and makes no mention of plant-based diagnostic tools.

Journal retracts ‘bizarre’ placebo effect paper

An Elsevier journal has retracted a study on the placebo effect coauthored by a researcher known for extreme claims that have failed to withstand scrutiny. The move comes after critics said the researchers misunderstood “what a ‘treatment effect’ is.”

The study, published in the Journal of Clinical Epidemiology in December 2024, analyzed 30 clinical trials examining treatments for a total of five conditions. The authors concluded “the placebo-effect is the major driver of treatment effects in clinical trials that alone explains 69% of the variance.” It has been cited once, according to Clarivate’s Web of Science.

The last author of the study is Harald Walach, who may be familiar to readers of Retraction Watch. In one now-retracted paper, Walach and his coauthors claimed the COVID-19 vaccines killed two people for every three deaths they prevented. In a different, also retracted paper, Walach and colleagues claimed children’s masks trap carbon dioxide. (They later republished the article in a different journal.)

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: